Journal Mobile Options
Table of Contents
Vol. 19, No. 4, 2001
Issue release date: 2001
Blood Purif 2001;19:361–369

Newly Developed Immobilized Polymyxin B Fibers Improve the Survival of Patients with Sepsis

Nemoto H. · Nakamoto H. · Okada H. · Sugahara S. · Moriwaki K. · Arai M. · Kanno Y. · Suzuki H.
Department of Nephrology and Kidney Disease Center, Saitama Medical College, Saitama, Japan

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: Sepsis and septic shock are still major causes of morbidity and mortality in spite of the availability of powerful and broadly active antibiotics. Methods: A prospective, open and randomized trial of the effect of immobilized polymyxin fibers (PMX-F) on the survival of patients with sepsis throughout a follow-up period of 28 days or until discharge, if earlier, was carried out. Ninety-eight patients were included who met at least 4 of the criteria for systemic inflammatory response syndrome due to infection. The patients were classified into three groups based on their Acute Physiology and Chronic Health Evaluation (APACHE) II score. Results: The overall survival rate was significantly improved by using PMX-F compared to the control group (41 vs. 11%) (p = 0.002). In patients with an APACHE II score less than 20, treatment with PMX-F was shown to improve outcome (65 vs. 19%) (p = 0.01). In cases of more severe sepsis with an APACHE II score of 20–29, PMX-F still maintained efficacy in improving outcome (40 vs. 11%) (p = 0.04). However, PMX-F treatment did not improve the survival rate in patients with an APACHE II score of greater than 30 (survival rate 7 vs. 0%) (p = 0.59). Conclusion: From these results, it is concluded that treatment with PMX-F in patients with sepsis is effective and prolongs the survival rate when applied at an early stage of sepsis. However, in severe sepsis, this therapy does not improve the survival rate.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Natanson C, Hoffman WD, Suffredini AF, Eichacker PQ, Danner RL: Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann Intern Med 1994;120:771–783.
  2. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101:1644–1655.
  3. Zeigler EJ, Fisher CJ, Sprung CL, et al: Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med 1991;324:429–436.
  4. Abraham E, Glauser MP, Butler T, Garbino J, Gelmont D, Laterre PF, Kudsk K, Bruining HA, Otto C, Tobin E, Zwingelstein C, Lesslauer W, Leighton A: p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group. JAMA 1997;277:1531–1538.
  5. Calandra T, Glauser MP, Schellekens J, Verhoef J: Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5:A prospective, double-blind, randomized trial. J Infect Dis 1988;158:312–319.
  6. Cohen J, Carlet J: INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-α in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med 1996;24:1431–1440.
  7. Fisher CJ Jr, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E, Schein RMH, Benjamin E: Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996;334:1697–1702.
  8. Greenman RL, Schein RH, Martin MA, Wenzel RP, MacIntyre NR, Emmanuel G, Chmel H, Kohler RB, McCarthy M, Plouffe J, Russell JA: A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group. JAMA 1991;266:1097–1102.
  9. Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of postsurgical infection. The Intravenous Immunoglobulin Collaborative Study Group. N Engl J Med 1992;327:234–240.
  10. Ahmed N, Christou N: Systemic inflammatory response syndrome: Interactions between immune cells and the endothelium. Shock 1996;6:S39–S42.

    External Resources

  11. Danner RL, Elia RJ, Hosseini JM, Wesley RA, Relly JM, Parrillo JE: Endotoxemia in human septic shock. Chest 1991;99:169–175.
  12. Guirao X, Lowry SF: Biologic control of injury and inflammation: Much more than too little or too late. World J Surg 1996;20:437–446.
  13. Kirkpatrick CJ, Bittinger F, Klein C, Hauptmann S, Klosterhalfen B: The role of microcirculation in multiple organ dysfunction syndrome (MODS): A review and perspective. Virchows Arch 1995;427:461–476.
  14. Dinarello CA, Wolff SM: The role of interleukin-1 in disease. N Engl J Med 1993;328:106–113.
  15. Alexander HR, Sheppard BC, Jensen JC, Langstein HN, Buresh CM, Venzon D, Walker EC, Fraker DL, Stovroff MC, Norton JA: Treatment with recombinant human tumor necrosis factor-alpha protects rats against the lethality, hypotension, and hypothermia of gram-negative sepsis. J Clin Invest 1991;88:34–49.

    External Resources

  16. Allendoerfer R, Magee DM, Smith JG, Bonewald L, Graybill JR: Induction of tumor necrosis factor-alpha in murine Candida albicans infection. J Infect Dis 1993;167:1168–1172.

    External Resources

  17. Van der Meer JW, Barza M, Wolff SM, Dinarello CA: A low dose of recombinant interleukin 1 protects granulocytopenic mice from lethal gram-negative infection. Proc Natl Acad Sci USA 1988;85:1620–1623.
  18. Hanasawa K, Tani T, Kodama M: New approach to endotoxic and septic shock by means of polymyxin B immobilized fiber. Surg Gynecol Obstet 1989;168:323–331.
  19. Jaber BL, Pereira BJG: Extracorporeal adsorbent-based strategies in sepsis. Am J Kidney Dis 1997;30(5 suppl 4):S44–S56.
  20. Shoji H, Tani T, Hanasawa K, Kodama M: Extracorporeal endotoxin removal by polymyxin B immobilized fiber cartridge: Designing and antiendotoxin efficacy in the clinical application. Ther Apher 1998;2:3–12.
  21. Aoki H, Kodama M, Tani T, Hanasawa K: Treatment of sepsis by extracorporeal elimination of endotoxin using polymyxin B-immobilized fiber. Am J Surg 1994;167:412–417.
  22. Knaus WA, Draper EA, Wagner DP, Zimmerman JE: APACHE II: A severity of disease classification system. Crit Care Med 1985;13:818–829.
  23. Cochran WG: Some methods for strengthening the common χ2 tests. Biometrics 1954;10:417–451.
  24. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719–748.
  25. Draper NR, Smith H: Applied Regression Analysis, ed 2. New York, Wiley, 1981.
  26. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:456–481.
  27. Ebihara I, Nakamura T, Shimada N, Shoji H, Koide H: Effect of hemoperfusion with polymyxin B-immobilized fiber on plasma endothelin-1 and endothelin-1 mRNA in monocytes from patients with sepsis. Am J Kidney Dis 1998;32:953–961.
  28. Nakamura T, Suzuki Y, Shimada N, Ebihara I, Shoji H, Koide H: Hemoperfusion with polymyxin B-immobilized fiber attenuates the increased plasma levels of thrombomodulin and von Willebrand factor from patients with septic shock. Blood Purif 1998;16:179–186.
  29. Kodama M, Tani T, Hanasawa K, Hirata K, Hirasawa H, Oda S, Otsuka T, Yamamoto Y, Kanesaka S, Takahashi Y, Maekawa K, Wakabayashi K, Tamakuma S, Sugimoto T: Treatment of sepsis by plasma endotoxin removal: Hemoperfusion using a polymyxin-B immobilized column. The PMX Clinical Study Group. J Endotoxin Res 1997;4:293–300.
  30. Lefering R, Neugebauer EAM: Steroid controversy in sepsis and septic shock: A meta-analysis. Crit Care Med 1995;23:1294–1303.
  31. Wenzel R, Bone RC, Feis A, et al: Results of a second double-blind, randomized, controlled trial of anti-endotoxin antibody E5 in gram-negative sepsis (abstract). Thirty-First Interscience Conference of Antimicrobial Agents and Chemotherapy, 1991, p 294.
  32. Morrison DC, Jacobs DM: Binding of polymyxin B to the lipid A portion of bacterial lipopolysaccharides. Immunochemistry 1976;13:813–818.
  33. Niwa M, Umeda M, Ohashi K: Inactivation and immobilization of endotoxin. A novel endotoxin binding substance, polymyxin sepharose. Jpn J Med Sci Biol 1982;35:114–115.
  34. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis C, Wenzel RP: The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 1995;273:117–123.
  35. Schlievert PM: Enhancement of host susceptibility to lethal endotoxin shock by staphylococcal pyrogenic exotoxin type C. Infect Immun 1982;36:123–128.

    External Resources

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50